Pharma Support Virtual Event Bag
Total Page:16
File Type:pdf, Size:1020Kb
#NANETSgoesVirtual PHARMA SUPPORT VIRTUAL EVENT BAG NANETS2020 MULTIDISCIPLINARY NET MEDICAL VIRTUAL SYMPOSIUM OCTOBER 2-3 2020 NANETS Multidisciplinary Net Medical Virtual Symposium - Pharma Support | 1 TABLE OF CONTENTS Diamond Supporters ................................................................... 3 Advanced Accelerator Applications Ipsen Platinum Supporter ..................................................................... 8 SunPharma Gold Supporter .......................................................................... 13 Curium Silver Supporters ....................................................................... 16 ITM Progenics TerSera Bronze Supporter ...................................................................... 34 Entrinsic 2 | 2020 NANETS Multidisciplinary Net Medical Virtual Symposium - Pharma Support DIAMOND SUPPORTERS 2020 NANETS Multidisciplinary Net Medical Virtual Symposium - Pharma Support | 3 The role of LUTATHERA® (lutetium Lu 177 dotatate) in patients with progressive GEP-NETs Presented by: Dr. Eric Liu, MD, FACS General Surgeon Neuroendocrine Specialist The Neuroendocrine Institute, Rocky Mountain Cancer Centers Denver, Colorado INDICATION: LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Click here to watch it online including foregut, midgut and hindgut neuroendocrine tumors in adults.1 IMPORTANT SAFETY INFORMATION1 WARNINGS AND PRECAUTIONS bronchoconstriction or other signs and symptoms of tumor-related hormonal Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and long-term cumulative radiation exposure and is associated with an increased risk electrolytes as indicated. for cancer. Radiation can be detected in the urine for up to 30 days following Embryo-Fetal Toxicity: LUTATHERA can cause fetal harm. Advise pregnant women LUTATHERA administration. Minimize radiation exposure to patients, medical of the potential risk to a fetus. Advise females of reproductive potential to use personnel, and household contacts during and after treatment with LUTATHERA effective contraception during treatment and for 7 months after the final dose. Advise consistent with institutional good radiation safety practices, patient management males with female partners of reproductive potential to use effective contraception procedures, Nuclear Regulatory Commission patient-release guidance, and during treatment and for 4 months after the final dose. Verify pregnancy status of instructions to the patient for follow-up radiation protection at home. females of reproductive potential prior to initiating LUTATHERA. Myelosuppression: In NETTER-1 clinical trial, myelosuppression occurred more Risk of Infertility: LUTATHERA may cause infertility in males and females. Radiation frequently in patients receiving LUTATHERA with long acting octreotide at the absorbed by testis and ovaries from the recommended cumulative LUTATHERA following rates (all grades/grade 3 or 4): anemia (81%/0), thrombocytopenia dose falls within the range in which temporary or permanent infertility can be (53%/1%), and neutropenia (26%/3%). Blood cell counts must be monitored prior expected following external beam radiotherapy. to, during, and after treatment. Withhold, reduce dose, or permanently discontinue based on severity of myelosuppression. ADVERSE REACTIONS The most common Grade 3-4 adverse reactions (≥ 4% with a higher incidence Secondary Myelodysplastic Syndrome and Leukemia: In NETTER-1, with in LUTATHERA arm) observed in NETTER-1 were lymphopenia (44%), increased a median follow-up time of 24 months, myelodysplastic syndrome (MDS) was GGT (20%), vomiting (7%), nausea (5%), elevated AST (5%), increased ALT (4%), reported in 2.7% of patients receiving LUTATHERA with long-acting octreotide. In hyperglycemia (4%), and hypokalemia (4%). ERASMUS, a Phase I/II clinical study, 16 patients (2.0%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to the development of MDS was In ERASMUS, the following serious adverse reactions have been observed with 28 months (9 to 41 months) and 55 months (32 to 155 months) for acute leukemia. a median follow-up time of more than 4 years after treatment with LUTATHERA: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension Renal Toxicity: Treatment with LUTATHERA will expose kidneys to radiation, which (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal may impair renal function. In ERASMUS <1% of patients developed renal failure crisis (1%). Patients should be counseled and monitored in accordance with the 3 to 36 months following LUTATHERA. Monitor serum creatinine and creatinine LUTATHERA Prescribing Information. clearance to assess changes in renal function. Advise patients to urinate frequently during and after administration of LUTATHERA. A concomitant intravenous infusion DRUG INTERACTIONS of amino acids before, during and after LUTATHERA administration is mandatory for Somatostatin and its analogs competitively bind to somatostatin receptors and may renal protection. Patients with baseline renal impairment may be at greater risk of interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each toxicity. Perform more frequent assessments of renal function in patients with mild LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA or moderate impairment. Withhold, reduce dose, or permanently discontinue based treatment as recommended. on severity of renal toxicity. Do not decrease the dose of amino acid solution if the dose of LUTATHERA is reduced. LUTATHERA has not been studied in patients with Corticosteroids can induce down-regulation of subtype 2 somatostatin receptors severe renal impairment (CrCL < 30 mL/min). (SST2). Avoid repeated administration of high doses of glucocorticosteroids during treatment with LUTATHERA. Hepatotoxicity: In ERASMUS, <1% of patients were reported to have hepatic tumor hemorrhage, edema, or necrosis, with one patient experiencing intrahepatic SPECIFIC POPULATIONS congestion and cholestasis. Patients with hepatic metastasis may be at increased Lactation: Because of the potential risk for serious adverse reactions in breastfed risk of hepatotoxicity due to radiation exposure. Monitor transaminases, bilirubin, infants, advise women not to breastfeed during treatment with LUTATHERA and for and serum albumin during treatment. Withhold, reduce dose, or permanently 2.5 months after the final dose. discontinue based on severity of hepatic impairment. To report SUSPECTED ADVERSE REACTIONS, contact Advanced Accelerator Neuroendocrine hormonal crisis: Manifesting with flushing, diarrhea, Applications USA, Inc. at 1-844-863-1930, or [email protected], bronchospasm and hypotension, neuroendocrine hormonal crisis occurred in <1% or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. of patients in ERASMUS and typically occurred during or within 24 hours following the initial LUTATHERA dose. Monitor patients for flushing, diarrhea, hypotension, Please see the full Prescribing Information. 1. LUTATHERA® [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; May 2020. This symposium is organized and sponsored by Advanced Accelerator Applications (AAA), a Novartis company. AAA-Lu177-US-0254 September 2020 TESTED & DEMONSTRATED PREFERENCE IN PRESTO1 SEE WHY PRESTO: LONG-ACTING SSA SYRINGE PREFERENCE STUDY To learn more about Somatuline Depot: A randomized, multinational, multicenter, noninterventional, simulated-use study: MOST NURSES • Objective: The primary objective of this study was to assess the preferences of nurses between theSOMATULINE DEPOT syringe and the SANDOSTATIN LAR DEPOT syringe PREFERRED THE • Participants: Nurses (N=90) with experience administering SOMATULINE DEPOT and SANDOSTATIN LAR • Method: Nurses attended a single testing session, during which they injected injection pads with each type of SOMATULINE DEPOT syringe twice before reporting their preferences. Data were collected using an anonymous, self-administered, Visit SomatulineDepotHCP.com web-based questionnaire 1 • Limitations: Limitations of this study included the need for a change in injection pad after 10 injection sessions SYRINGE due to clogging issues which resulted in 2 separate cohorts, and that the injections performed were simulated. There were imbalances noted in the sociodemographics and the clinical settings of nurses that potentially introduced bias in the reporting of preferences. Another limitation was that IN A SIMULATED-USE STUDY some nurse respondents were from the Contract Research Organizations (CRO) network. No assessment of efficacy or safety should be made based on this study *The Somatuline Depot delivery system was updated in response to feedback, provided by acromegaly and NET patients, nurses, and caregivers, during 4 formative studies regarding the design and functionality of updated delivery device prototypes. The subsequent human factors validation study in 2017 reviewed the use of the updated delivery system by intended users in the intended use environment. Most common errors among HCPs (N=35) were failure to follow correct procedure if the syringe was dropped (34%) and failure to inspect the product before administration (34%); no